Is Natera (NTRA) Fully Priced Or Still A Bargain On Conference Buzz?

Natera (NTRA) stepped into the spotlight on 14 September 2026 with a presentation at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, drawing fresh attention to the stock’s recent run.

That conference slot lands after a strong run for Natera, with the share price up 2.63% on the day and showing a 54.91% 90 day share price return. The 1 year total shareholder return of 100.43% and very large 3 year total shareholder return point to sustained momentum.

Scan beyond Natera’s conference buzz and see how other high growth stories with strong fundamentals stack up in our hand picked 16 high quality undiscovered gems.

After a move like this, Natera now asks a sharper question: Does the current valuation still leave enough upside to justify the risk you take buying in here?

Most Popular Narrative: 24% Overvalued

Natera last closed at $350.78, which is well above the most followed narrative fair value estimate of $282.14 that uses a 7.13% discount rate. That gap is shaping how many investors think about the balance between future growth expectations and what is already reflected in today’s price.

Analysts are assuming Natera's revenue will grow by 18.8% annually over the next 3 years.

Analysts assume that profit margins will increase from -9.0% today to 7.2% in 3 years time.

See why 17 investors see Natera as 24% overvalued.

Result: Fair Value of $282.14 (OVERVALUED)

Still, the story around Natera can change quickly if clinical trials disappoint or if growing R&D and commercial spend weigh on the path to profitability.

Find out about the key risks to this Natera narrative.

Another View On Natera’s Valuation

The analyst narrative leans toward Natera looking 24% overvalued at $350.78. The SWS DCF model points in the opposite direction. It values the stock at $595.47, which frames the current quote as trading about 41% below that cash flow based estimate. Which story do you think is closer to reality?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Natera for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 34 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Plenty of investors now see Natera through a bullish lens, so move quickly, test those assumptions against the data, and weigh the 3 key rewards

Looking for more investment ideas beyond Natera?

If Natera has sharpened your appetite for opportunity, do not stop here. Let the screener surface fresh ideas that match how you already like to invest.

• Target potential upside with companies that combine quality fundamentals and attractive pricing through our carefully filtered 34 high quality undervalued stocks.
• Protect your capital focus by scanning for businesses with healthier finances using the robust list of solid balance sheet and fundamentals (22 results).
• Lean into resilience and sleep easier by tracking stocks that carry lower risk profiles in the curated 11 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com